Collaboration Agreement Signed Between Genetic Technologies and Translational Genomics Research Institute

Genetic Technologies Limited
, a provider of world-leading genetic risk assessment test products today announced that it has signed a 3-year Collaboration Agreement with TGen. TGen, an affiliate of City of Hope in Duarte, California, is an Arizona-based, non-profit biomedical research institute dedicated to conducting ground-breaking research with life-changing results. TGen physicians and scientists work to understand the genetic components of both common and complex diseases (including cancer, neurological disorders, and infectious disease), and rare childhood disorders. They are also focused on the translation of clinically useful genomics discoveries into the clinic. Key Features of this Collaboration Agreement between GTG and TGen:-  GTG and TGen will cooperate in the design feasibility analysis of clinical research studies to support the clinical application of GTG's polygenic risk tests;  The initial focus of the studies will be the clinical utility of the GeneType Breast and Colorectal Cancer risk tests developed by GTG. This aims to demonstrate the value of these tests for clinicians when assessing individual risk profiles;  GTG and TGen will identify appropriate clinical partners to participate in the studies. Genetic Technologies Limited
ABN 17 009 212 328 60-66 Hanover Street Fitzroy Victoria 3065 Australia +61 3 8412 7000 Once completed, it is expected that these studies will provide strong clinical evidence to support the use of GTGs polygenic risk tests as an important routine tool in predicting individual disease risk. They can then assist clinicians to develop individual risk management programmes for improved prevention and treatment of these diseases. The clinical utility data obtained during the course of the collaboration will form an important component of a comprehensive reimbursement strategy. The terms of the Agreement are confidential, however, key features include that GTG and TGen will cooperate in the design and conduct of clinical utility studies for a suite of polygenic risk tests for common diseases to be developed and made available in the US market. Genetic Technologies' Chief Scientific Officer Dr Richard Allman said, "I am excited to be collaborating with such a prestigious organisation as TGen. The clinical utility studies we envisage are intended to translate our GeneType tests into daily clinical use." David Duggan, Ph.D., associate professor of TGen commented: "The GeneType Breast and Colorectal Cancer risk prediction tests have the potential to personalize clinical management. Results from these studies are expected to positively affect clinical decision-making for a sizeable number of patients. We are excited to partner with this industry-leader."

Posted In: NewsPress Releases

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.